{"id":"https://openalex.org/W2986436720","doi":"https://doi.org/10.1182/blood-2019-122494","title":"A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma","display_name":"A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2986436720","doi":"https://doi.org/10.1182/blood-2019-122494","mag":"2986436720"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-122494","doi":"https://doi.org/10.1182/blood-2019-122494","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-122494","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053904944","display_name":"Nina D. Shah","orcid":"https://orcid.org/0000-0002-1971-8173","observed_orcids":["https://orcid.org/0000-0002-1971-8173"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nina D. Shah","raw_affiliation_strings":["University of California, San Francisco, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, San Francisco, San Francisco, CA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089990813","display_name":"Cameron John Turtle","orcid":"https://orcid.org/0000-0002-4722-4461","observed_orcids":["https://orcid.org/0000-0002-4722-4461"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cameron J. Turtle","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024384857","display_name":"Andrew J. Cowan","orcid":"https://orcid.org/0000-0002-1880-7094","observed_orcids":["https://orcid.org/0000-0002-1880-7094","https://orcid.org/0000-0003-2326-2727"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew J. Cowan","raw_affiliation_strings":["Department of Medicine, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084789778","display_name":"Julio C. Ch\u00e1vez","orcid":"https://orcid.org/0000-0002-2045-6238","observed_orcids":["https://orcid.org/0000-0002-2045-6238"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julio C. Chavez","raw_affiliation_strings":["Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082326885","display_name":"Lihua Elizabeth Budde","orcid":"https://orcid.org/0000-0003-1464-5494","observed_orcids":["https://orcid.org/0000-0003-1464-5494"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lihua E Budde","raw_affiliation_strings":["City of Hope Comprehensive Cancer Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope Comprehensive Cancer Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059340436","display_name":"Mario Q. Marcondes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mario Q. Marcondes","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103176744","display_name":"Zachary Lee","orcid":"https://orcid.org/0009-0004-9516-9024","observed_orcids":["https://orcid.org/0009-0004-9516-9024"]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zachary Lee","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103941866","display_name":"Wei Lin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Lin","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011698346","display_name":"Jonathan Zalevsky","orcid":"https://orcid.org/0000-0003-2707-1709","observed_orcids":["https://orcid.org/0000-0003-2707-1709"]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Zalevsky","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071236842","display_name":"Mary Ann Tagliaferri","orcid":"https://orcid.org/0000-0002-1043-2662","observed_orcids":["https://orcid.org/0000-0002-1043-2662"]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Tagliaferri","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060313982","display_name":"Krina K. Patel","orcid":"https://orcid.org/0000-0002-8894-027X","observed_orcids":["https://orcid.org/0000-0002-8894-027X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Krina K. Patel","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"4459","last_page":"4459"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.012000000104308128,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/il-15","display_name":"IL-15","score":0.7260000109672546},{"id":"https://openalex.org/keywords/il-15-receptor-alpha","display_name":"IL-15 receptor alpha","score":0.8759999871253967},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.8199999928474426},{"id":"https://openalex.org/keywords/relapsed-or-refractory-hematologic-malignancies","display_name":"relapsed or refractory hematologic malignancies","score":0.921999990940094},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.9909999966621399},{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.9340000152587891},{"id":"https://openalex.org/keywords/nk-cell-therapy","display_name":"NK cell therapy","score":0.6269999742507935},{"id":"https://openalex.org/keywords/nk-cell-dysfunction","display_name":"NK cell dysfunction","score":0.5149999856948853},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.597000002861023},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.6790000200271606},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8569999933242798},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6200000047683716},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.6309999823570251},{"id":"https://openalex.org/keywords/cytokine-therapy","display_name":"cytokine therapy","score":0.41100001335144043},{"id":"https://openalex.org/keywords/chimeric-antigen-receptor-t-cells","display_name":"chimeric antigen receptor T cells","score":0.35100001096725464}],"concepts":[{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.6824333667755127},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5777629613876343},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.47306811809539795},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4474336504936218},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.43403300642967224},{"id":"https://openalex.org/C2908885563","wikidata":"https://www.wikidata.org/wiki/Q410130","display_name":"Aldesleukin","level":4,"score":0.425545334815979},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.41335874795913696},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4099913239479065},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4082622528076172},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39570552110671997},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37574315071105957},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.36787861585617065},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3666590452194214},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.34715336561203003},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.3268641531467438},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2063690721988678},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.1790035367012024},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.16270548105239868},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.15227222442626953}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-122494","doi":"https://doi.org/10.1182/blood-2019-122494","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-122494","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4200445440","https://openalex.org/W3175520955","https://openalex.org/W3098290807","https://openalex.org/W4288037647","https://openalex.org/W3213094971","https://openalex.org/W2955318634","https://openalex.org/W2955491009","https://openalex.org/W3212871396","https://openalex.org/W2986103032","https://openalex.org/W3113343303"],"abstract_inverted_index":{"Background:":[0],"IL-15-mediated":[1],"responses":[2,68],"have":[3,7,76,116,155,396],"been":[4,117],"shown":[5,156],"to":[6,36,51,88,123,198,208,375,431],"a":[8,44,303,372,441],"crucial":[9],"role":[10],"in":[11,119,145,169,185,215,354,364,388,452,456],"the":[12,70,120,130,139,146,206,219,258,282,312,327,331,420,428],"development,":[13],"function,":[14],"and":[15,25,40,91,135,194,213,235,337,379,436,448,466],"survival":[16,196],"of":[17,56,142,221,239,270,279,308,330,340,349,403,427,438,450,473,485,497,522,535,547,572,597,625,653,667,710,723,734,747,758,769],"CD8+":[18],"T":[19,27,189,200],"cells,":[20,24],"natural":[21],"killer":[22],"(NK)":[23],"NK":[26,79,100,143,160,210],"cells.":[28],"However,":[29],"exploiting":[30],"native":[31],"IL-15":[32,46,57],"is":[33,43,287],"challenging":[34],"due":[35],"its":[37],"unfavorable":[38],"pharmacokinetics":[39],"tolerability.":[41,380],"NKTR-255":[42,59,184,203,280,293,314,350,363,385,439,451],"polymer-conjugated":[45],"that":[47,78,183,409],"retains":[48],"binding":[49],"affinity":[50],"IL-15Ra,":[52],"maintaining":[53],"full":[54],"spectrum":[55],"biology.":[58],"also":[60],"exhibits":[61],"improved":[62],"pharmacokinetics,":[63],"thereby":[64],"providing":[65],"sustained":[66],"pharmacodynamic":[67],"without":[69],"need":[71,207],"for":[72,302,333,338],"daily":[73],"dosing.":[74],"Studies":[75],"indicated":[77],"cells":[80,96,101,144,190,201],"from":[81,104,638],"patients":[82,174,217,241,264,272,290,365,389,457],"with":[83,165,187,218,242,250,366,386,390,392,405,454,458,636],"multiple":[84],"myeloma":[85,126],"(MM)":[86],"appear":[87],"be":[89,255,266,300,324,352,416],"dysfunctional,":[90],"successful":[92],"activity":[93],"against":[94],"MM":[95,121,247,368,391],"requires":[97],"highly":[98],"active":[99],"ideally":[102],"activated":[103],"immunomodulatory":[105],"agents":[106,115],"or":[107,244,248,369,487,499,524,537,549,574,599,627,655,669,712,725,736,749,760,771],"cytokine":[108],"support.":[109],"In":[110,150,227,257],"recent":[111],"years,":[112],"several":[113],"new":[114],"introduced":[118],"landscape":[122],"engage":[124],"NK-mediated":[125],"cell":[127,161,211],"elimination,":[128],"including":[129],"CD38-targeting":[131],"monoclonal":[132],"antibody":[133],"daratumumab,":[134],"elotuzumab,":[136],"further":[137,376],"supporting":[138],"anti\u2010MM":[140],"effect":[141],"post-autologous":[147],"transplant":[148],"setting.":[149],"non-Hodgkin":[151],"lymphoma":[152,173],"(NHL),":[153],"studies":[154],"low":[157],"peripheral":[158],"blood":[159],"counts":[162],"are":[163,430],"associated":[164],"poor":[166],"clinical":[167,412],"outcomes":[168],"diffuse":[170],"large":[171],"B-cell":[172],"receiving":[175],"R-CHOP":[176],"chemotherapy":[177],"regimens.":[178],"Recently":[179],"published":[180],"data":[181],"indicate":[182],"combination":[186,453],"CAR":[188,199],"decreases":[191],"tumor":[192],"burden":[193],"increases":[195],"compared":[197],"alone.":[202],"may":[204],"address":[205],"boost":[209],"quality":[212],"numbers":[214],"these":[216],"purpose":[220],"aiding":[222],"current":[223],"approved":[224,422],"therapies.":[225],"Methods:":[226],"this":[228],"phase":[229,345],"1,":[230],"open-label,":[231],"multi-center,":[232],"dose":[233,236,259,285,334,347,356],"escalation":[234,260,328],"expansion":[237,357],"study":[238,332,429],"NKTR-255,":[240],"relapsed":[243],"refractory":[245],"(r/r)":[246],"NHL":[249,370],"no":[251,406],"available":[252],"therapies":[253],"will":[254,265,274,291,299,323,351,361,383,415],"eligible.":[256],"portion,":[261],"approximately":[262],"46":[263],"enrolled.":[267],"Successive":[268],"cohorts":[269],"3":[271,400],"each":[273],"receive":[275,292],"single":[276,442],"increasing":[277],"doses":[278],"until":[281],"maximum":[283],"tolerated":[284],"(MTD)":[286],"determined.":[288],"All":[289],"once":[294],"every":[295],"three":[296,309],"weeks.":[297],"Patients":[298],"observed":[301],"dose-limiting":[304],"toxicity":[305],"(DLT)":[306],"window":[307],"weeks":[310],"following":[311],"first":[313],"dose.":[315],"A":[316,360],"two-parameter":[317],"Bayesian":[318],"logistic":[319],"regression":[320],"model":[321],"(BLRM)":[322],"used":[325],"during":[326],"part":[329],"level":[335],"selection":[336],"determination":[339],"MTDs.":[341],"The":[342,424],"selected":[343],"recommended":[344],"2":[346],"(RP2D)":[348],"evaluated":[353],"two":[355],"cohorts.":[358],"Cohort":[359,381],"expand":[362],"r/r":[367,459],"as":[371,440,444,446],"salvage":[373],"regimen":[374],"characterize":[377],"safety":[378,447],"B":[382],"combine":[384],"daratumumab":[387,455],"progressive":[393],"disease":[394],"who":[395],"had":[397],"at":[398,419],"least":[399],"prior":[401],"lines":[402],"therapy":[404],"other":[407],"regimens":[408],"would":[410],"confer":[411],"benefit.":[413],"Daratumumab":[414],"administered":[417],"IV":[418],"standard":[421],"regimen.":[423],"primary":[425],"objectives":[426,462],"evaluate:":[432],"safety,":[433],"tolerability,":[434],"MTD,":[435],"RP2D":[437],"agent,":[443],"well":[445],"tolerability":[449],"MM.":[460],"Secondary":[461],"include":[463],"measures":[464],"biomarker":[465],"pharmacokinetic":[467],"analyses.":[468],"Figure":[469],"Disclosures":[470],"Shah:":[471],"University":[472],"California,":[474],"San":[475],"Francisco:":[476],"Employment;":[477],"Nkarta:":[478],"Consultancy,":[479,491,515,528,541,694,698,817],"Membership":[480,492,517,530,542,567,592,620,648,662,705,718,729,742,753,764],"on":[481,493,518,531,543,568,593,621,649,663,706,719,730,743,754,765],"an":[482,494,519,532,544,569,594,622,650,664,707,720,731,744,755,766],"entity's":[483,495,520,533,545,570,595,623,651,665,708,721,732,745,756,767],"Board":[484,496,521,534,546,571,596,624,652,666,709,722,733,746,757,768],"Directors":[486,498,523,536,548,573,598,626,654,668,711,724,735,748,759,770],"advisory":[488,500,525,538,550,575,586,600,606,613,628,656,670,676,683,713,726,737,750,761,772],"committees;":[489,501,526,539,551,576,601,629,657,671,727,751,762],"Kite:":[490],"Celgene,":[502,815],"Janssen,":[503],"Bluebird":[504],"Bio,":[505],"Sutro":[506],"Biopharma:":[507],"Research":[508,511,589,642,689,695,699,702,806,818],"Funding;":[509,512,590,643,690,696,700,807],"Poseida:":[510],"Bristol-Myers":[513],"Squibb:":[514],"Honoraria,":[516,529],"Amgen:":[527],"Teneobio:":[540],"Genentech,":[552],"Seattle":[553],"Genetics,":[554],"Oncopeptides,":[555,808],"Karoypharm,":[556],"Surface":[557],"Oncology,":[558],"Precision":[559,644,810],"biosciences":[560],"GSK,":[561],"Nektar,":[562,809],"Amgen,":[563],"Indapta":[564,577],"Therapeutics,":[565,803],"Sanofi:":[566,691],"Therapeutics:":[578,582,617,631,780,785,788,793,798],"Equity":[579,618,646,660,782,790,795,800],"Ownership.":[580,783,791,796,801],"Turtle:Nektar":[581],"Other:":[583,603,610,673,680],"Ad":[584,604,611,674,681],"hoc":[585,605,612,675,682],"board":[587,607,614,677,684],"member,":[588],"T-CURX:":[591],"Allogene:":[602],"member;":[608,615,678],"Humanigen:":[609],"Eureka":[616],"Ownership,":[619,647,661],"Juno":[630,639],"Patents":[632],"&":[633],"Royalties:":[634],"Co-inventor":[635],"staff":[637],"Therapeutics;":[640],"pending,":[641],"Biosciences:":[645,659],"Caribou":[658],"Kite/Gilead:":[672],"Novartis:":[679,717],"member.":[685],"Cowan:Cellectar:":[686],"Consultancy;":[687,692,813],"Juno:":[688],"Janssen:":[693,816],"Celgene:":[697,763],"Abbvie:":[701,805],"Funding.":[703,819],"Chavez:Kite:":[704],"committees,":[714,738],"Speakers":[715,739],"Bureau;":[716,740],"Genentech:":[728],"Bayer:":[741],"Karyopharm:":[752],"committees.":[773],"Budde:F.":[774],"Hoffmann-La":[775],"Roche":[776],"Ltd:":[777],"Consultancy.":[778],"Marcondes:Nektar":[779],"Employment,":[781,789,794,799],"Lee:Nektar":[784],"Employment.":[786],"Lin:Nektar":[787],"Zalevsky:Nektar":[792],"Tagliaferri:Nektar":[797],"Patel:Poseida":[802],"Cellectis,":[804],"Biosciences,":[811],"BMS:":[812],"Takeda,":[814]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2019-11-22T00:00:00"}